Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung ...

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted ...

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) ...

A recent publication by the British Thoracic Society offers the first long-term analysis of the UK Idiopathic Pulmonary ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

A recent publication on the real-world treatment in the US shows that only 26.5% of patients diagnosed with IPF started on antifibrotic treatment, with 43% discontinuing the medication.

First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung models Trial results published in Nature Communications ...

Blocking Piezo2, a protein receptor that senses mechanical forces in tissues, may be a new way to slow IPF progression, per a ...

R&D, strategic partnerships, and rising IPF cases, leading to innovative therapies and improved patient outcomes ...

GRI Bio is developing Natural Killer T cell modulators for treatment of inflammatory, fibrotic and autoimmune diseases. It reported the results from its continuing Phase 2a study demonstrating ...